Skip to content

FreezIng bReaST Cancer in Brazil: a Before-after Study

Evaluation of Cryoablation in the Local Treatment of Early Breast Cancer

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05398497
Acronym
FIRST
Enrollment
30
Registered
2022-06-01
Start date
2022-09-15
Completion date
2024-07-15
Last updated
2022-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Breast Neoplasms

Keywords

cryoablation, cryotherapy, breast cancer

Brief summary

Image-guided tumor ablation is a non-surgical, minimally invasive therapy available for local therapy of some carcinomas as an alternative to surgical treatment. This study assesses whether cryoablation can be used as an alternative to surgery in cases of early invasive breast carcinoma.

Detailed description

Purpose: To evaluate the effectiveness of cryoablation in the local treatment of breast cancer, through the absence of neoplastic cells (invasive or in situ). Outline 1. Core biopsy 2. Mammogram 3. Magnetic resonance imaging 4. Ultrasound 5. Tumor Cryoablation 6. Mammogram (post-cryoablation) 7. Magnetic resonance imaging (post-cryoablation) 8. Ultrasound (post-cryoablation) 9. Surgery 10. Evaluation of outcomes

Interventions

DEVICECryoablation

Cryoablation will be performed under ultrasound guidance.

Sponsors

Hospital do Coracao
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Unifocal primary invasive breast carcinoma * Pathological report should be complete (with the result of ER, PR , HER2, KI67 and FISH report of ERBB2 gene if necessary) * Maximum tumor size ≤2.5 cm in its greatest diameter * Ultrasound visible lesion

Exclusion criteria

* Multifocal or multicentric invasive breast carcinoma * Ductal carcinoma in-situ * Breast cancer with skin involvement * Clinically positive axilla (N1, N2 or N3) * Distance from lesion and skin less than 5 mm * Prior neoadjuvant systemic therapy for breast cancer * Distant metastasis

Design outcomes

Primary

MeasureTime frameDescription
Tumor ablation1 monthSuccessful tumor ablation will be defined as absence of residual viable invasive or in situ carcinoma in the surgical specimen.

Secondary

MeasureTime frameDescription
Negative predictive value of magnetic resonance imaging (MRI)14 days and 28 daysMagnetic resonance imaging will be conducted between 14 to 28 days after cryoablation. Negative predictive value of MRI will be calculated according to the pathological report after the traditional surgery. Negative predictive value = number of the patients who is pathologically negative divided by the number of patients who is MRI negative.
Accuracy of conventional imaging methods (mammography and ultrasound)14 days and 28 daysMammography and ultrasound will be conducted between 14 to 28 days after cryoablation. Accuracy of conventional imaging methods will be calculated according to the pathological report after the traditional surgery.
Measurement of the ice ball by ultrasound14 days and 28 daysTo compare the baseline tumor size, ultrasound measurement of the ice ball, and the pathological result.

Countries

Brazil

Contacts

Primary ContactVanessa M Sanvido, PhD
dravanessasanvido@gmail.com551138864688
Backup ContactAfonso P Nazário, Professor
nazarioafonso@hotmail.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 21, 2026